Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence (DRES-POCAI)
Session Description
San Ysidro Health (SYH), a Federally Qualified Health Center (FQHC) serving over 121,000 San Diego County resident from medically underserved minority communities that are low-income, underinsured, with high rates of diabetes mellitus (DM) and low rates of diabetic retinopathy (DR) screening (54%), has identified an innovative method to address unmet medical needs in diabetic eye care by enhancing and modifying existing clinical practices through integrating point-of-care (POC) artificial intelligence (AI) technology for DR screening. The DRES – POCAI intervention will be integrated into SYH’s electronic health records (EHR) and increase access to DR screening within the primary care setting. This new model will improve quality performance levels, facilitate clinical decision-making process, accelerate timely identification of DR, improve linkage to DM guideline-concordant care, educate/engage patients, and therefore leading to an improved overall management of patient eye health.
Video Recording
Speaker
Fatima Muñoz de Flores
Fatima Muñoz de Flores joined San Ysidro Health as the Director of the Research and Health Promotion Department in 2016, as she was recently promoted as the Associate Vice President of Health Support Services. She completed her medical and Master’s in Public Health training in Mexico and a postdoctoral training in the Division of Global Public Health, University of California San Diego with over 15 years of health promotion and research experience focused on epidemiology and implementation of health prevention programs specifically among underserved communities.
Fatima is also a Co-Investigator from San Ysidro Health in research study that has been conducted in collaboration with UCSD to address individual, social, and contextual factors related to access to, and acceptance of, the COVID-19 vaccine among Latinx and Black adults in San Diego. Most recently, by the recommendation of the California State Senate Fatima was selected to be a Member of the new Advisory Council for the California Initiative to Advance Precision Medicine (CIAPM).
Sonia C Tucker, MBA
Sonia is the Vice President of Population Health for San Ysidro Health. Sonia has been working for Federally Qualified Health Centers for over a decade. Sonia’s s work has led to improvement in the health care organizations she has worked for, achieving numerous qualities of care recognitions from organizations such as the National Committee for Quality Assurance (NCQA), the Health Resource and Services Administration (HRSA), and many more.
Edgar Diaz, MD
Edgar is the Director of Research and Health Promotion at San Ysidro Health. He has over 20 years of experience in basic and clinical research, including large, multidisciplinary collaborative projects and observational and interventional studies at various academic institutions. At San Ysidro Health, Edgar’s work focuses on improving community health outcomes through research-driven programs and initiatives
Featured Discussant
Alastair Denniston, MA, MRCP, FRCOphth, PhD, University Hospitals Birmingham NHSFT, UK
Alastair Denniston is a consultant ophthalmologist (eye specialist) at University Hospitals Birmingham leading research into the use of health data research and artificial intelligence to improve patient care in the ‘real world’. He is Professor at the University of Birmingham, and part of the Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital/UCL.
Alastair has particular interest in how we can ensure that the innovation within the broad field of ‘artificial intelligence’ is translated efficiently but safely to benefit patients. This includes improving the reporting standards of trials (CONSORT-AI and SPIRIT-AI), helping define the regulatory framework for AI in healthcare, and working with HDRUK and other relevant organisations to support the best of these innovations right through the implementation pathway.
other real-world AI events
Precision Resuscitation with Crystalloids in Sepsis (PRECISE trial)
September 12, 2024